Quanterix Corporation reported first-quarter 2026 revenue of $36.4 million, up 20% from $30.3 million a year earlier, driven by product and service growth across its Simoa and spatial biology platforms. GAAP gross margin was 42.7%, while adjusted gross margin improved to 50.9% from 49.7%.
The company posted a GAAP net loss of $17.5 million (or $0.37 per share), modestly better than the $20.5 million loss in 2025, and an adjusted EBITDA loss of $9.8 million versus $11.3 million. Quanterix ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash.
Management highlighted progress on integrating Akoya Biosciences, citing $85 million of cost synergies realized and a terminated off-market diagnostics contract that drove significant one-time charges and income. The Alzheimer’s diagnostics franchise continues to expand, with several clinical utility studies expected to complete and an FDA decision on a 510(k) application anticipated in the second half of 2026.
For full-year 2026, Quanterix reaffirmed revenue guidance of $169–$174 million, GAAP gross margin of 41–45% and adjusted gross margin of 49–53%. The company continues to expect cash flow breakeven in the second half of 2026 and to finish the year with roughly $100 million in cash and no debt.
Quanterix Corp Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. He exercised 130 restricted stock units that converted into 130 shares of common stock on a one-for-one basis. To cover tax obligations, 39 common shares were disposed of through a tax-withholding transaction, not an open-market sale.
Following these transactions, Miller directly holds 32,613 shares of common stock and 549 restricted stock units that remain outstanding from a prior grant of 6,278 RSUs made on September 23, 2022.
Quanterix Corporation is holding its 2026 annual stockholder meeting virtually at 10:00 a.m. ET on June 9, 2026 via meetnow.global/QTRX2026. Holders of common stock as of April 14, 2026, when 47,064,988 shares were outstanding, may vote.
Stockholders will vote on electing two directors to one-year terms, an advisory approval of named executive officer compensation, an advisory ratification of KPMG LLP as independent auditor for 2026, and approval of an amended and restated 2017 Employee, Director and Consultant Equity Incentive Plan, plus any other properly presented business.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common stock and had shares withheld to cover taxes. On April 15, 2026, he acquired a total of 1,558 shares of common stock through multiple RSU conversions, all at a stated price of $0.00 per share.
To satisfy tax obligations related to these vesting events, 467 shares of common stock were disposed of at $3.60 per share in tax-withholding transactions. Following these transactions, Miller directly held 32,522 shares of Quanterix common stock.
Quanterix Corp Chief Financial Officer Sriram Vandana reported routine equity compensation activity involving restricted stock units that converted into common stock. On April 15, 2026, restricted stock units converted into common stock on a one-for-one basis, delivering 263, 514 and 1,056 shares in separate tranches.
Related common stock entries show 263, 514 and 1,056-share acquisitions at a price of $0.00 per share. To satisfy tax obligations, 79, 154 and 315 shares of common stock were withheld at $3.60 per share as tax-withholding dispositions, rather than open-market sales.
Following these transactions, the filing shows Sriram Vandana directly holding 28,713 shares of Quanterix common stock. The derivative section lists no remaining restricted stock units tied to these specific conversions, underscoring that the reported activity reflects compensation vesting and associated tax withholding.
DONNELLY WILLIAM P reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp Executive Chair William P. Donnelly received 6,178 shares of Common Stock as a stock grant. The shares were awarded at a stated price of $0.00 per share as a grant or award transaction, rather than an open-market purchase or sale.
According to the disclosure, this stock was granted in lieu of cash fees for Donnelly’s service on Quanterix’s Board of Directors and its committees for the first quarter of 2026. Following this award, Donnelly directly holds a total of 154,127 shares of Quanterix Common Stock.
Mendel Scott reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp director Scott Mendel received a grant of 4,310 shares of common stock as compensation. The shares were granted in lieu of cash fees for his service on the company’s Board of Directors and its committees for the first quarter of 2026. Following this award, he directly holds 12,527 shares.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common shares and had a portion withheld for taxes. On March 31, 2026, he converted 229 restricted stock units, which convert to common stock on a one-for-one basis, into the same number of common shares at a stated price of $0.00 per share.
To cover tax obligations, 69 common shares were disposed of through tax-withholding transactions at $3.52 per share, leaving him with a net increase of 160 common shares. Following these transactions, Miller directly owned 31,431 shares of Quanterix common stock. The restricted stock units exercised were part of prior grants from April 7, 2022 and September 23, 2022 that vest over time.
The Vanguard Group amended its Schedule 13G/A to report zero beneficial ownership of Quanterix Corp common stock. The filing (Amendment No. 2) explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately. The schedule states Amount beneficially owned: 0 and Percent of class: 0%. The amendment is signed by Ashley Grim on 03/27/2026.